Exact Sciences Corporation (NASDAQ: EXAS) has successfully completed its merger with Abbott Laboratories, a transaction valued at approximately $21 billion. The merger, which was finalized on March 23, 2026, positions Exact as a wholly owned subsidiary of Abbott. Under the terms of the merger agreement, shareholders of Exact will receive $105.00 in cash for each share of common stock they hold, excluding dissenting shares and certain excluded shares. This significant cash payout reflects a premium for Exact's shareholders and is expected to enhance Abbott's portfolio in the diagnostics sector. The merger was facilitated through a series of supplemental indentures that modified the rights of Exact's convertible senior notes, allowing for a conversion into cash based on the merger consideration. Following the merger, Exact's common stock will be delisted from the Nasdaq, and the company intends to suspend its reporting obligations under the Securities Exchange Act. This strategic move is anticipated to streamline operations and focus on integrating Exact's innovative cancer screening technologies into Abbott's broader healthcare offerings. The completion of this merger marks a pivotal moment for both companies, as they aim to leverage their combined strengths to drive growth and innovation in the healthcare market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.